-
1
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
the ION-2 Investigators
-
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, the ION-2 Investigators. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483-1493. http://dx.doi.org/10.1056/NEJMoa1316366.
-
(2014)
N Engl J Med
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
Lawitz, E.4
Gordon, S.C.5
Schiff, E.6
Nahass, R.7
Ghalib, R.8
Gitlin, N.9
Herring, R.10
Lalezari, J.11
Zh, Y.12
Pockros, P.J.13
Di Bisceglie, A.M.14
Arora, S.15
Subramanian, G.M.16
Zhu, Y.17
Dvory-Sobol, H.18
Yang, J.C.19
Pang, P.S.20
Symonds, W.T.21
McHutchison, J.G.22
Muir, A.J.23
Sulkowski, M.24
Kwo, P.25
more..
-
2
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
the ION-1 Investigators
-
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero- Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, the ION-1 Investigators. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889-1898. http://dx.doi.org/10.1056/NEJMoa1402454.
-
(2014)
N Engl J Med
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
Chojkier, M.4
Gitlin, N.5
Puoti, M.6
Romero- Gomez, M.7
Zarski, J.P.8
Agarwal, K.9
Buggisch, P.10
Foster, G.R.11
Brau, N.12
Buti, M.13
Jacobson, I.M.14
Subramanian, G.M.15
Ding, X.16
Mo, H.17
Yang, J.C.18
Pang, P.S.19
Symonds, W.T.20
McHutchison, J.G.21
Muir, A.J.22
Mangia, A.23
Marcellin, P.24
more..
-
3
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
AI444040 Study Group
-
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM, AI444040 Study Group. 2014. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:211-221. http://dx.doi.org/10.1056/NEJMoa1306218.
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
Reddy, K.R.4
Hassanein, T.5
Jacobson, I.6
Lawitz, E.7
Lok, A.S.8
Hinestrosa, F.9
Thuluvath, P.J.10
Schwartz, H.11
Nelson, D.R.12
Everson, G.T.13
Eley, T.14
Wind-Rotolo, M.15
Huang, S.P.16
Gao, M.17
Hernandez, D.18
McPhee, F.19
Sherman, D.20
Hindes, R.21
Symonds, W.22
Pasquinelli, C.23
Grasela, D.M.24
more..
-
4
-
-
84892761609
-
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
-
Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. 2014. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146:420-429. http://dx.doi.org/10.1053/j.gastro.2013.10.057.
-
(2014)
Gastroenterology
, vol.146
, pp. 420-429
-
-
Everson, G.T.1
Sims, K.D.2
Rodriguez-Torres, M.3
Hezode, C.4
Lawitz, E.5
Bourliere, M.6
Loustaud-Ratti, V.7
Rustgi, V.8
Schwartz, H.9
Tatum, H.10
Marcellin, P.11
Pol, S.12
Thuluvath, P.J.13
Eley, T.14
Wang, X.15
Huang, S.P.16
McPhee, F.17
Wind-Rotolo, M.18
Chung, E.19
Pasquinelli, C.20
Grasela, D.M.21
Gardiner, D.F.22
more..
-
5
-
-
84906814530
-
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study
-
Study Team HALLMARK-DUAL
-
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, Study Team HALLMARK-DUAL. 2014. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384:1597-1605. http://dx.doi.org/10.1016/S0140-6736(14)61059-X.
-
(2014)
Lancet
, vol.384
, pp. 1597-1605
-
-
Manns, M.1
Pol, S.2
Jacobson, I.M.3
Marcellin, P.4
Gordon, S.C.5
Peng, C.Y.6
Chang, T.T.7
Everson, G.T.8
Heo, J.9
Gerken, G.10
Yoffe, B.11
Towner, W.J.12
Bourliere, M.13
Metivier, S.14
Chu, C.J.15
Sievert, W.16
Bronowicki, J.P.17
Thabut, D.18
Lee, Y.J.19
Kao, J.H.20
McPhee, F.21
Kopit, J.22
Mendez, P.23
Linaberry, M.24
Hughes, E.25
Noviello, S.26
more..
-
6
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
Study PEARLIV
-
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR, Study PEARL-III, Study PEARLIV. 2014. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983-1992. http://dx.doi.org/10.1056/NEJMoa1402338.
-
(2014)
N Engl J Med
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
Cohen, D.4
Luo, Y.5
Cooper, C.6
Tam, E.7
Marinho, R.T.8
Tsai, N.9
Nyberg, A.10
Box, T.D.11
Younes, Z.12
Enayati, P.13
Green, S.14
Baruch, Y.15
Bhandari, B.R.16
Caruntu, F.A.17
Sepe, T.18
Chulanov, V.19
Janczewska, E.20
Rizzardini, G.21
Gervain, J.22
Planas, R.23
Moreno, C.24
Hassanein, T.25
Xie, W.26
King, M.27
Podsadecki, T.28
Reddy, K.R.29
Pearl-Iii, S.30
more..
-
7
-
-
80051676859
-
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews
-
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. 2011. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571-583. http://dx.doi.org/10.1016/S0140-6736(11)61097-0.
-
(2011)
Lancet
, vol.378
, pp. 571-583
-
-
Nelson, P.K.1
Mathers, B.M.2
Cowie, B.3
Hagan, H.4
Des Jarlais, D.5
Horyniak, D.6
Degenhardt, L.7
-
8
-
-
84929924393
-
Prevalence of HIV, hepatitis C and depression among people who inject drugs in the Kinondoni municipality in Dar es Salaam, Tanzania, abstr 473/poster 113
-
San Diego, CA, 15 to 20 June
-
Nyandindi C, Mbwambo J, McCurdy S, Lambdin B, Copenhaver M, Bruce R. 2013. Prevalence of HIV, hepatitis C and depression among people who inject drugs in the Kinondoni municipality in Dar Es Salaam, Tanzania, abstr 473/poster 113. 75th Annu Meet College Problems Drug Dependence, San Diego, CA, 15 to 20 June 2013.
-
(2013)
75th Annu Meet College Problems Drug Dependence
, vol.2013
-
-
Nyandindi, C.1
Mbwambo, J.2
McCurdy, S.3
Lambdin, B.4
Copenhaver, M.5
Bruce, R.6
-
9
-
-
77649275644
-
Methadone as HIV prevention: High volume methadone sites to decrease HIV incidence rates in resource limited settings
-
Bruce RD. 2010. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy 21:122-124. http://dx.doi.org/10.1016/j.drugpo.2009.10.004.
-
(2010)
Int J Drug Policy
, vol.21
, pp. 122-124
-
-
Bruce, R.D.1
-
10
-
-
84940940324
-
-
Gendelman HE, Grant I, Everall IP, Fox HS, Gelband HA, Lipton SA, Swindells S (Ed), Neurology of AIDS, 3rd Ed. Oxford University Press, New York, NY
-
Bruce RD. 2011. Medical interventions for addiction, p 581-600. In Gendelman HE, Grant I, Everall IP, Fox HS, Gelband HA, Lipton SA, Swindells S (ed), Neurology of AIDS, 3rd ed. Oxford University Press, New York, NY.
-
(2011)
Medical Interventions for Addiction
, pp. 581-600
-
-
Bruce, R.D.1
-
11
-
-
84887015331
-
Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial
-
Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. 2013. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-outcomes of a randomized trial. Drug Alcohol Depend 133:376-382. http://dx.doi.org/10.1016/j.drugalcdep.2013.06.024.
-
(2013)
Drug Alcohol Depend
, vol.133
, pp. 376-382
-
-
Otiashvili, D.1
Piralishvili, G.2
Sikharulidze, Z.3
Kamkamidze, G.4
Poole, S.5
Woody, G.E.6
-
12
-
-
78651012481
-
Pharmacologic comparison of the optical isomers of methadon
-
Scott CC, Robbins EB, Chen KK. 1948. Pharmacologic comparison of the optical isomers of methadon. J Pharmacol Exp Ther 93:282-286.
-
(1948)
J Pharmacol Exp Ther
, vol.93
, pp. 282-286
-
-
Scott, C.C.1
Robbins, E.B.2
Chen, K.K.3
-
13
-
-
0014867155
-
Localization of d- and l-methadone after intraventricular injection into rat brains
-
Ingoglia NA, Dole VP. 1970. Localization of d- and l-methadone after intraventricular injection into rat brains. J Pharmacol Exp Ther 175: 84-87.
-
(1970)
J Pharmacol Exp Ther
, vol.175
, pp. 84-87
-
-
Ingoglia, N.A.1
Dole, V.P.2
-
14
-
-
0038193696
-
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
-
Wang JS, DeVane CL. 2003. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31:742-747. http://dx.doi.org/10.1124/dmd.31.6.742.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 742-747
-
-
Wang, J.S.1
DeVane, C.L.2
-
15
-
-
0347383736
-
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19
-
Gerber JG, Rhodes RJ, Gal J. 2004. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44. http://dx.doi.org/10.1002/chir.10303.
-
(2004)
Chirality
, vol.16
, pp. 36-44
-
-
Gerber, J.G.1
Rhodes, R.J.2
Gal, J.3
-
16
-
-
33947412998
-
Enantiomeric metabolic interactions and stereoselective human methadone metabolism
-
Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. 2007. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 321:389-399. http://dx.doi.org/10.1124/jpet.106.117580.
-
(2007)
J Pharmacol Exp Ther
, vol.321
, pp. 389-399
-
-
Totah, R.A.1
Allen, K.E.2
Sheffels, P.3
Whittington, D.4
Kharasch, E.D.5
-
17
-
-
0031843967
-
Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4
-
Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y. 1998. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26:818-821.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 818-821
-
-
Kobayashi, K.1
Yamamoto, T.2
Chiba, K.3
Tani, M.4
Shimada, N.5
Ishizaki, T.6
Kuroiwa, Y.7
-
18
-
-
17844409048
-
In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways
-
Picard N, Cresteil T, Djebli N, Marquet P. 2005. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 33:689-695. http://dx.doi.org/10.1124/dmd.105.003681.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 689-695
-
-
Picard, N.1
Cresteil, T.2
Djebli, N.3
Marquet, P.4
-
19
-
-
69949093628
-
Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP glucuronosyltransferases
-
Chang Y, Moody DE. 2009. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP glucuronosyltransferases. Drug Metab Lett 3:101-107. http://dx.doi.org/10.2174/187231209788654117.
-
(2009)
Drug Metab Lett
, vol.3
, pp. 101-107
-
-
Chang, Y.1
Moody, D.E.2
-
20
-
-
73149100796
-
Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes
-
Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. 2010. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40-45. http://dx.doi.org/10.1124/dmd.109.029546.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 40-45
-
-
Rouguieg, K.1
Picard, N.2
Sauvage, F.L.3
Gaulier, J.M.4
Marquet, P.5
-
21
-
-
77952035218
-
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
-
Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org/10.1038/nature08960.
-
(2010)
Nature
, vol.465
, pp. 96-100
-
-
Gao, M.1
Nettles, R.E.2
Belema, M.3
Snyder, L.B.4
Nguyen, V.N.5
Fridell, R.A.6
Serrano-Wu, M.H.7
Langley, D.R.8
Sun, J.H.9
O'Boyle, D.R.10
Lemm, J.A.11
Wang, C.12
Knipe, J.O.13
Chien, C.14
Colonno, R.J.15
Grasela, D.M.16
Meanwell, N.A.17
Hamann, L.G.18
-
22
-
-
84940919158
-
-
HCV infection, abstr O111. 49th Annu Meet Eur Assoc Study Liver, London, United Kingdom, 9 to 13 April 2014
-
Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass R, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, Symonds WT, McHutchison JG, Morgan T, Chung RT. 2014. Safety and efficacy of treatment with interferon-free, ribavirin-free combination of sofosbuvir - GS-5816 for 12 weeks in treatment-naive patients with genotypes 1-6 HCV infection, abstr O111. 49th Annu Meet Eur Assoc Study Liver, London, United Kingdom, 9 to 13 April 2014.
-
(2014)
Safety and Efficacy of Treatment with Interferon-free Ribavirin-free Combination of Sofosbuvir - GS-5816 for 12 Weeks in Treatment-naive Patients with Genotypes
, pp. 1-6
-
-
Everson, G.T.1
Tran, T.T.2
Towner, W.J.3
Davis, M.N.4
Wyles, D.5
Nahass, R.6
McNally, J.7
Brainard, D.M.8
Han, L.9
Doehle, B.10
Mogalian, E.11
Symonds, W.T.12
McHutchison, J.G.13
Morgan, T.14
Chung, R.T.15
-
23
-
-
82455188181
-
Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
-
Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, Demicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Carlos Lopez-Talavera J, Grasela DM. 2011. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54:1956-1965. http://dx.doi.org/10.1002/hep.24609.
-
(2011)
Hepatology
, vol.54
, pp. 1956-1965
-
-
Nettles, R.E.1
Gao, M.2
Bifano, M.3
Chung, E.4
Persson, A.5
Marbury, T.C.6
Goldwater, R.7
Demicco, M.P.8
Rodriguez-Torres, M.9
Vutikullird, A.10
Fuentes, E.11
Lawitz, E.12
Carlos Lopez-Talavera, J.13
Grasela, D.M.14
-
24
-
-
84892728051
-
Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4, abstr O-15
-
Cambridge, MA, 26 to 27 June 2013. (Presentation)
-
Bifano M, Sevinsky H, Stonier M, Jiang H, Bertz RJ. 2013. Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4, abstr O-15. 8th Int Workshop Clin Pharmacol Hepatitis Ther, Cambridge, MA, 26 to 27 June 2013. (Presentation available at http://regist2.virology-education.com/2013/8hepcam/docs/21-Bertz.pdf.)
-
(2013)
8th Int Workshop Clin Pharmacol Hepatitis Ther
-
-
Bifano, M.1
Sevinsky, H.2
Stonier, M.3
Jiang, H.4
Bertz, R.J.5
-
25
-
-
0041665111
-
The clinical opiate withdrawal scale (COWS)
-
Wesson DR, Ling W. 2003. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 35:253-259. http://dx.doi.org/10.1080/02791072.2003.10400007.
-
(2003)
J Psychoactive Drugs
, vol.35
, pp. 253-259
-
-
Wesson, D.R.1
Ling, W.2
-
26
-
-
0023231245
-
Two new rating scales for opiate withdrawal
-
Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. 1987. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13:293-308. http://dx.doi.org/10.3109/00952998709001515.
-
(1987)
Am J Drug Alcohol Abuse
, vol.13
, pp. 293-308
-
-
Handelsman, L.1
Cochrane, K.J.2
Aronson, M.J.3
Ness, R.4
Rubinstein, K.J.5
Kanof, P.D.6
-
27
-
-
27144449749
-
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
-
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. 2005. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 19:1635-1641. http://dx.doi.org/10.1097/01.aids.0000183628.20041.f2.
-
(2005)
AIDS
, vol.19
, pp. 1635-1641
-
-
Friedland, G.1
Andrews, L.2
Schreibman, T.3
Agarwala, S.4
Daley, L.5
Child, M.6
Shi, J.7
Wang, Y.8
O'Mara, E.9
-
28
-
-
84861963822
-
A sensitive and accurate liquid chromatography- tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine
-
Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME. 2012. A sensitive and accurate liquid chromatography- tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine. J Chromatogr A 1245:117-121. http://dx.doi.org/10.1016/j.chroma.2012.05.028.
-
(2012)
J Chromatogr A
, vol.1245
, pp. 117-121
-
-
Jiang, H.1
Zeng, J.2
Kandoussi, H.3
Liu, Y.4
Wang, X.5
Bifano, M.6
Cojocaru, L.7
Ryan, J.8
Arnold, M.E.9
-
29
-
-
0025958371
-
Sample size determination for bioequivalence assessment by means of confidence intervals
-
Diletti E, Hauschke D, Steinijans VW. 1991. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29:1-8.
-
(1991)
Int J Clin Pharmacol Ther Toxicol
, vol.29
, pp. 1-8
-
-
Diletti, E.1
Hauschke, D.2
Steinijans, V.W.3
-
30
-
-
84924293707
-
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
-
Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R. 2014. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther 19:511-519. http://dx.doi.org/10.3851/IMP2718.
-
(2014)
Antivir Ther
, vol.19
, pp. 511-519
-
-
Bifano, M.1
Sevinsky, H.2
Hwang, C.3
Kandoussi, H.4
Jiang, H.5
Grasela, D.6
Bertz, R.7
-
31
-
-
84937759225
-
An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects
-
Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz R. 2015. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Invest 35:281-289. http://dx.doi.org/10.1007/s40261-015-0279-5.
-
(2015)
Clin Drug Invest
, vol.35
, pp. 281-289
-
-
Bifano, M.1
Adamczyk, R.2
Hwang, C.3
Kandoussi, H.4
Marion, A.5
Bertz, R.6
-
32
-
-
84891829801
-
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: Ritonavir-boosted atazanavir, efavirenz and tenofovir
-
Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R. 2013. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 18:931-940. http://dx.doi.org/10.3851/IMP2674.
-
(2013)
Antivir Ther
, vol.18
, pp. 931-940
-
-
Bifano, M.1
Hwang, C.2
Oosterhuis, B.3
Hartstra, J.4
Grasela, D.5
Tiessen, R.6
Velinova-Donga, M.7
Kandoussi, H.8
Sevinsky, H.9
Bertz, R.10
-
33
-
-
84940946984
-
Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects abstr 79
-
Washington, DC, 26 to 28 May
-
Song I, Jerva F, Zong J, Choukour M, Wynne B, Buchanan A, Eley T, Huang S, Ross L. 2015. Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects, abstr 79. 16th Int Workshop Clin Pharmacol HIV and Hepatitis Ther, Washington, DC, 26 to 28 May 2015.
-
(2015)
16th Int Workshop Clin Pharmacol HIV and Hepatitis Ther
, vol.2015
-
-
Song, I.1
Jerva, F.2
Zong, J.3
Choukour, M.4
Wynne, B.5
Buchanan, A.6
Eley, T.7
Huang, S.8
Ross, L.9
-
34
-
-
84928569640
-
Drugdrug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir
-
31 January
-
Menon R, Badri P, Wang T, Polepally A, Zha J, Khatri A, Wang H, Hu B, Coakley E, Podsadecki T, Awni W, Dutta S. 31 January 2015. Drugdrug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir. J Hepatol http://dx.doi.org/10.1016/j.jhep.2015.01.026.
-
(2015)
J Hepatol
-
-
Menon, R.1
Badri, P.2
Wang, T.3
Polepally, A.4
Zha, J.5
Khatri, A.6
Wang, H.7
Hu, B.8
Coakley, E.9
Podsadecki, T.10
Awni, W.11
Dutta, S.12
-
35
-
-
84940905515
-
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
-
31 March
-
Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE. 31 March 2015. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol http://dx.doi.org/10.1016/j.jhep.2015.03.029.
-
(2015)
J Hepatol
-
-
Lalezari, J.1
Sullivan, J.G.2
Varunok, P.3
Galen, E.4
Kowdley, K.V.5
Rustgi, V.6
Aguilar, H.7
Felizarta, F.8
McGovern, B.9
King, M.10
Polepally, A.R.11
Cohen, D.E.12
-
36
-
-
0028833349
-
Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling
-
Ohtani M, Kotaki H, Sawada Y, Iga T. 1995. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 272:505-510.
-
(1995)
J Pharmacol Exp Ther
, vol.272
, pp. 505-510
-
-
Ohtani, M.1
Kotaki, H.2
Sawada, Y.3
Iga, T.4
-
37
-
-
0030911470
-
Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine
-
Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. 1997. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 281:428-433.
-
(1997)
J Pharmacol Exp Ther
, vol.281
, pp. 428-433
-
-
Ohtani, M.1
Kotaki, H.2
Nishitateno, K.3
Sawada, Y.4
Iga, T.5
-
38
-
-
67651208452
-
Buprenorphine: The basic pharmacology revisited
-
Cowan A. 2007. Buprenorphine: the basic pharmacology revisited. J Addict Med 1:68-72. http://dx.doi.org/10.1097/ADM.0b013e31806c9202.
-
(2007)
J Addict Med
, vol.1
, pp. 68-72
-
-
Cowan, A.1
-
39
-
-
0035028389
-
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist
-
Huang P, Kehner GB, Cowan A, Liu-Chen LY. 2001. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
-
(2001)
J Pharmacol Exp Ther
, vol.297
, pp. 688-695
-
-
Huang, P.1
Kehner, G.B.2
Cowan, A.3
Liu-Chen, L.Y.4
-
40
-
-
33646574334
-
Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation
-
Megarbane B, Marie N, Pirnay S, Borron SW, Gueye PN, Risede P, Monier C, Noble F, Baud FJ. 2006. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 212:256-267. http://dx.doi.org/10.1016/j.taap.2005.08.002.
-
(2006)
Toxicol Appl Pharmacol
, vol.212
, pp. 256-267
-
-
Megarbane, B.1
Marie, N.2
Pirnay, S.3
Borron, S.W.4
Gueye, P.N.5
Risede, P.6
Monier, C.7
Noble, F.8
Baud, F.J.9
-
41
-
-
84890099630
-
Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioiddependent individuals
-
Masson CL, Rainey PM, Moody DE, McCance-Katz EF. 2014. Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioiddependent individuals. Am J Addict 23:34-40. http://dx.doi.org/10.1111/j.1521-0391.2013.12052.x.
-
(2014)
Am J Addict
, vol.23
, pp. 34-40
-
-
Masson, C.L.1
Rainey, P.M.2
Moody, D.E.3
McCance-Katz, E.F.4
|